Darbepoetin Alfa Articles
Amgen in firing line as Supreme Court OKs anemia drug lawsuits
28 February 2013
New guideline from ASH and ASCO recommends caution regarding ESA use in cancer patients
28 October 2010
US FDA advisory panel backs continued use of Amgen’s Aranesp and Epogen pre-dialysis, but calls for more studies
19 October 2010
US FDA to review use of anemia drugs from Amgen and Johnson & Johnson; Commissioner calls for shift in traditional testing methods
15 October 2010
FDA agrees plan requiring Amgen and J&J unit to educate doctors and patients on risks of anemia drugs
17 February 2010
Amgen's fourth quarter 2009 earnings slightly below consensus analyst’s expectations
26 January 2010
Court blocks Roche’s sales of Mircera in USA until 2014, as Amgen prevails in EPO patent dispute
23 December 2009
Amgen’s Aranesp did not meet endpoints and increased risk of stroke; firm accused of kickbacks
2 November 2009
Cost-cutting helps Amgen lift 3rd quarter 2009 EPS 21%
22 October 2009
Japan stock market week to May 4, 2009
5 May 2009
Falling profit on low sales for Amgen
27 April 2009
Merck & Co unveils new biosimilars unit
15 December 2008
Stock Commentary - New York week to Oct 27, 2008
3 November 2008
Amgen's 3rd-qtr 2008 profit leaps to $1.16B
3 November 2008
Cochrane meta-analysis confirms ESA AE profile
13 October 2008
Japan stock market week to August 25, 2008
1 September 2008
FDA forces label-change for Amgen anemia drugs
1 September 2008
Amgen initiates Ph III Aranesp study in HF
18 August 2008
Amgen earnings down but outlook still up
4 August 2008
Denosumab increases BMD in ADT patients
21 July 2008
Amgen and Ortho Bio settle antitrust suit
21 July 2008
EMEA recommends new warnings on epoetins
7 July 2008
Amgen reports nearly flat 1st qtr
5 May 2008
ESAs get EU label restrictions
10 March 2008
Amgen sells Takeda Japanese rights to 13 drugs in a deal that could be worth up to $1.2B
11 February 2008
Stock Commentary - New York week to Dec 10, 2007
17 December 2007
Amgen in discussions to update US ESA labels
17 December 2007
B-MS to cut 10% of workforce in a bid to save $1.5B in time for loss of Plavix patent
17 December 2007
Amgen issued with subpoenas
19 November 2007
Dynepo demonstrates reduced angiogenesis in preclinical trial
12 November 2007
US insurer updates anemia drug policies
29 October 2007
Amgen wins in Roche Mircera patent suit
29 October 2007
Dosing begins in Ph III Hematide study
22 October 2007
No chemo benefit with Amgen's Aranesp
8 October 2007
Amgen and EMEA discuss ESA prescribing
8 October 2007
Amgen to cut 675 jobs in California and Rhode Island
27 September 2007
Stock Commentary - New York week to Sept 17, 2007
24 September 2007
FDA panel votes against restricting ESA dose
17 September 2007
Aranesp has no negative survival impact in SCLC
17 September 2007
US oncology docs want CMS anemia drug review
10 September 2007
Amgen to save $1B in restructuring after Aranesp sales drop
20 August 2007
Stock Commentary - New York week to Aug 13, 2007
20 August 2007
Affymax' Hematide to enter Ph III studies
23 July 2007
France's drug spending up 1.4% says CNAM
25 June 2007
Amgen buys US renal specialist for $420M
11 June 2007
Japan stock market week to June 4, 2007
11 June 2007
CMS moves quickly on ESA coverage limits
21 May 2007
Amgen's 1st-qtr 2007 net profits up 11%
30 April 2007
Stock Commentary - New York week to Mar 12, 2007
26 March 2007
Stock Commentary - New York week to March 5, 2007
12 March 2007
Safety concerns linked to Aranesp in cancer trial
26 February 2007
Fresenius in new deal with Amgen
12 February 2007
Stock Commentary - New York week to Jan 29, 2007
5 February 2007
Roche submits more data for Mircera BLA
22 December 2006
Ph IIIb study shows benefits of extended Aranesp dosing
22 December 2006
Amgen responds to anemia drug controversy
11 December 2006
CREATE results support NeoRecormon label
27 November 2006
Roche's Mircera is first renal anemia drug to work on a twice-monthly dosing regimen
27 November 2006
Study: Procrit cheaper than rival anemia drugs
6 November 2006
Stock Commentary - New York week to Oct 16, 2006
23 October 2006
FDA requests more data on Amgen's Aranesp
23 October 2006
Amgen's 2nd-qtr 2006 sales up 14% to $3.6B
31 July 2006
J&J's record 2nd-qtr 2006 sales boost profit 10%
24 July 2006
ITC judge rules peg-EPO covered by exemption
17 July 2006
Amgen sees $1B profits in 1st-qtr 2006
24 April 2006
Amgen to explore anemia in CV patients
20 March 2006
Amgen starts $1B Puerto Rico site expansion
13 February 2006
Roche delays CERA US FDA filing, Amgen gains
13 February 2006
US FDA issues revised safety warning on Epogen, Aranesp and Procrit
12 December 2005
FDA licenses to Amgen production facilities
12 September 2005
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
